Lupin: Lupin Receives U.S
Lupin (LUPIN) filed a disclosure titled "Lupin Receives U.S". The company is valued at about ₹91,286 crore.
What happened
Lupin (LUPIN) filed a disclosure with the exchanges on 2 November 2026 at 06:05 PM titled "Lupin Receives U.S".
Company snapshot
Lupin is a mid-cap company in the Healthcare sector, with a market value of about ₹91,286 crore.
The stock last traded at ₹1,996.5, against a 52-week range of ₹1,892.9–₹2,529.5 (21.1% below the high).
Before this filing the shares had moved −2.0% over the month and −16.7% over three months. Average daily turnover over the last 20 sessions was about ₹131 crore.
Promoters held 46.85% at the end of Q1 FY27. Foreign institutions owned 22.42% and domestic institutions 24.65%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,268 | 1,219 | 26.7 |
| Q2 FY26 | 7,048 | 1,477.9 | 32.36 |
| Q3 FY26 | 7,168 | 1,175.6 | 25.74 |
| Q4 FY26 | 7,475 | 1,460.3 | 31.96 |
| Q1 FY27 | 8,277 | 1,415 | 30.95 |
What history shows
BCEIE's records show 12 or more previous approval filings from the company since May 2026.
After those filings, the stock fell 0.6% on average the next trading day and was down 0.6% on average after five days (8 filings with price data).
Across 116 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +1.2% over five days; 54% of them rose the next day.
Market-wide, 1,547 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 8 Oct 2026 | Lupin Receives U.S. FDA Approval for Phytonadione Injectable… | −0.1% | +1.3% |
| 28 Sept 2026 | Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban… | −1.9% | −3.0% |
| 4 Sept 2026 | A press release dated September 04, 2026, titled "Lupin Receives U.S | −0.3% | −0.7% |
| 20 Aug 2026 | Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A. | −1.0% | −3.0% |
| 31 Jul 2026 | Approval | −1.2% | −2.4% |
What to watch
- 3 November 2026: Board meeting — Financial Results/Other business matters.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.